NMPA Approves China's First Topical JAK Inhibitor Cream for Vitiligo
Start here
On January 30, 2026, China's National Medical Products Administration approved ruxolitinib phosphate cream for the treatment of vitiligo, making it the first topical JAK inhibitor available in China for the skin condition. The product, marketed under a brand name rendered in Chinese sources as Bailand or Ruvtos, offers vitiligo patients a new topical treatment option. The approval marks a milestone for JAK inhibitor therapies in Chinese dermatology. Details about the drug's developer, its mechanism of action, and the clinical data supporting the approval have not been disclosed in the coverage so far.
Written by a model from the reports · updated 3 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- mp.weixin.qq.comPickNMPA Approves Ruxolitinib Phosphate Cream, China's First Topical JAK Inhibitor for Vitiligo
On January 30, 2026, the NMPA approved ruxolitinib phosphate cream (brand name Bailand/Ruvtos, English name uncertain) for marketing in China for vitiligo. The source describes it as China's first topical JAK inhibitor for vitiligo but provides no mechanism of action, developer, or clinical data.
Heat trend for this story
Heat now 9·Peak in the comparable set 10 (Oct 23 12:00)·Change over 24h in the comparable set –·Participants now 1
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.